This technical article describes the opportunities and risks associated with highly potent active pharmaceutical ingredients (HPAPIs). While these compounds often have properties that enable them to target disease more selectively at significantly lower dosages and with reduced side effects than traditional APIs, they are highly toxic until they reach finished solid or liquid form. Because of the exposure risk, handling of HPAPIs requires facilities with specialized equipment, infrastructure, and expertise from preclinical development through commercial manufacture to protect employees. These are described, as are innovative dosage form technologies that can help reduce occupational risk during the manufacturing process.
Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.
We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.
By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.